* Inotiv Inc reported a quarterly adjusted loss of $1.86 per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of three analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from -74 cents to -34 cents per share.
* Revenue fell 21.4% to $119.04 million from a year ago; analysts expected $129.78 million.
* Inotiv Inc's reported EPS for the quarter was a loss of $1.86.
* The company reported a quarterly loss of $48.08 million.
* Inotiv Inc shares had fallen by 80.6% this quarter and lost 42.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Inotiv Inc is $10.00 This summary was machine generated from LSEG data May 15 at 10:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.54 -1.86 Missed
Dec. 31 2023 -0.85 -0.60 Beat
Sep. 30 2023 -0.33 -0.38 Missed
Jun. 30 2023 -0.10 0.07 Beat
Comments